Johnson & Johnson (JNJ) is one of the biggest healthcare players in the world. However, it has been impacted by growing competition and pricing pressure in the industry in recent years and has revised its strategy. The company has witnessed recuperating sales in its medical devices business along with improving dynamics in its consumer business, which has encountered some litigation recently. The company’s pharmaceuticals business has performed steadily, with key trial data being announced. Let’s look at analysts’ recommendations for JNJ stock.